VivoSeq
Cardiovascular

Chronic Venous Insufficiency

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Chronic Venous Insufficiency is an early-stage landscape with 0 programs across 2 companies. The most active players are Boehringer Ingelheim, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed9 · 69%
Unknown status3 · 23%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers
Active, not recruiting·SSerenaGroup, Inc.·Phase 2·NCT03154619·80 enrolled
Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT02191254·245 enrolled
Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
Completed·Takeda logoTakeda·Phase 4·NCT01848210·829 enrolled
Antistax® in Patients With Chronic Venous Insufficiency
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT02191280·260 enrolled
Iliac Vein Stenting in Advanced Chronic Venous Insufficiency
Completed·IInstituto Dante Pazzanese de Cardiologia·Phase 4·NCT02149212·50 enrolled
Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT02191163·71 enrolled
Clinical Non-inferiority Study Between Diosmin 600mg & Diosmin + Hesperidin in Symptomatic Chronic Venous Insufficiency
Completed·FFundação Educacional Serra dos Órgãos·Phase 4·NCT03471910·120 enrolled
Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT00855179·250 enrolled
Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency
Completed·AAbbott·Phase 4·NCT00835822·216 enrolled
Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT02184234·65 enrolled
Tissue Engineered Veins in Patients With Chronic Venous Insufficiency
Unknown status·VVerigraft AB·Phase 1·NCT03784131·15 enrolled
Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon
Unknown status·LLaboratório Teuto Brasileiro S/A·Phase 3·NCT01477281·82 enrolled
Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)
Unknown status·—·Phase 3·NCT01110512·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)